CL2016002548A1 - Derivados de tubulisina - Google Patents
Derivados de tubulisinaInfo
- Publication number
- CL2016002548A1 CL2016002548A1 CL2016002548A CL2016002548A CL2016002548A1 CL 2016002548 A1 CL2016002548 A1 CL 2016002548A1 CL 2016002548 A CL2016002548 A CL 2016002548A CL 2016002548 A CL2016002548 A CL 2016002548A CL 2016002548 A1 CL2016002548 A1 CL 2016002548A1
- Authority
- CL
- Chile
- Prior art keywords
- tubulisin
- derivatives
- tubulisine
- antibody
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
<p>COMPUESTOS DERIVADOS DE TUBULISINA; UN CONJUGADO ANTICUERPO-FÁRMACO; COMPOSICION FARMACEUTICA; METODO PARA TRATAR EL CANCER</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461978460P | 2014-04-11 | 2014-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016002548A1 true CL2016002548A1 (es) | 2017-02-24 |
Family
ID=54264545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016002548A CL2016002548A1 (es) | 2014-04-11 | 2016-10-06 | Derivados de tubulisina |
Country Status (19)
Country | Link |
---|---|
US (2) | US9427479B2 (es) |
EP (1) | EP3129362A4 (es) |
JP (1) | JP2017510661A (es) |
KR (1) | KR20160142392A (es) |
CN (1) | CN106458942A (es) |
AR (1) | AR100006A1 (es) |
AU (1) | AU2015243379B2 (es) |
CA (1) | CA2945318A1 (es) |
CL (1) | CL2016002548A1 (es) |
EA (1) | EA032203B1 (es) |
IL (1) | IL247822A0 (es) |
MA (1) | MA39862A (es) |
MX (1) | MX2016013373A (es) |
NZ (1) | NZ725131A (es) |
PH (1) | PH12016501995A1 (es) |
SG (1) | SG11201608203RA (es) |
TW (1) | TW201625662A (es) |
UY (1) | UY36075A (es) |
WO (1) | WO2015157594A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20160142392A (ko) * | 2014-04-11 | 2016-12-12 | 메디뮨 엘엘씨 | 튜부리신 유도체 |
JP2017512765A (ja) | 2014-04-11 | 2017-05-25 | メディミューン,エルエルシー | 二重特異性her2抗体 |
CA2977589A1 (en) | 2015-02-25 | 2016-09-01 | William Marsh Rice University | Desacetoxytubulysin h and analogs thereof |
AU2016352967A1 (en) | 2015-11-10 | 2018-06-21 | Medimmune, Llc | Binding molecules specific for ASCT2 and uses thereof |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
EP3411371A1 (en) * | 2016-02-01 | 2018-12-12 | Pfizer Inc | Tubulysin analogs and methods for their preparation |
SG11201808979UA (en) | 2016-04-15 | 2018-11-29 | Macrogenics Inc | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
EP3661963A1 (en) | 2017-08-01 | 2020-06-10 | MedImmune, LLC | Bcma monoclonal antibody-drug conjugate |
MX2020006192A (es) * | 2017-12-31 | 2020-08-20 | Hangzhou Dac Biotech Co Ltd | Un conjugado de un analogo de tubulisina con enlazadores ramificados. |
CN109456212A (zh) * | 2018-12-03 | 2019-03-12 | 康化(上海)新药研发有限公司 | 一种沙库比曲中间体的合成方法 |
TWI753252B (zh) * | 2019-05-03 | 2022-01-21 | 中國大陸商杭州多禧生物科技有限公司 | 含支鏈連接體的Tubulysin同系物偶聯物 |
US20230115871A1 (en) * | 2019-06-24 | 2023-04-13 | Hangzhou Dac Biotech Co., Ltd | A conjugate of a cytotoxic agent to a cell binding molecule with branched linkers |
EP4171653A2 (en) * | 2020-06-24 | 2023-05-03 | Regeneron Pharmaceuticals, Inc. | Tubulysins and protein-tubulysin conjugates |
WO2022053650A1 (en) | 2020-09-11 | 2022-03-17 | Medimmune Limited | Therapeutic b7-h4 binding molecules |
US20230183358A1 (en) | 2021-11-10 | 2023-06-15 | Astrazeneca Ab | Antibody molecules and conjugates |
GB202117928D0 (en) | 2021-12-11 | 2022-01-26 | Cancer Research Tech Ltd | Immunotherapy for cancer |
WO2024002938A1 (en) | 2022-06-27 | 2024-01-04 | Astrazeneca Ab | Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7064211B2 (en) * | 2002-03-22 | 2006-06-20 | Eisai Co., Ltd. | Hemiasterlin derivatives and uses thereof |
EP1828776A4 (en) * | 2004-12-09 | 2010-03-17 | Eisai R&D Man Co Ltd | TUBULINISOTYPE SEARCH IN CANCER THERAPY WITH HEMIASTERLINANALOGES |
IT1394860B1 (it) * | 2009-07-22 | 2012-07-20 | Kemotech S R L | Composti farmaceutici |
US8394922B2 (en) * | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
KR101733853B1 (ko) * | 2011-11-17 | 2017-05-08 | 화이자 인코포레이티드 | 세포독성 펩티드 및 그의 항체 약물 접합체 |
AU2012348017A1 (en) * | 2011-12-05 | 2014-07-03 | Igenica Biotherapeutics, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
WO2014126836A1 (en) * | 2013-02-14 | 2014-08-21 | Bristol-Myers Squibb Company | Tubulysin compounds, methods of making and use |
JP2017512765A (ja) * | 2014-04-11 | 2017-05-25 | メディミューン,エルエルシー | 二重特異性her2抗体 |
KR20160142392A (ko) * | 2014-04-11 | 2016-12-12 | 메디뮨 엘엘씨 | 튜부리신 유도체 |
WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
-
2015
- 2015-04-10 KR KR1020167031176A patent/KR20160142392A/ko unknown
- 2015-04-10 US US14/683,196 patent/US9427479B2/en not_active Expired - Fee Related
- 2015-04-10 JP JP2017504616A patent/JP2017510661A/ja active Pending
- 2015-04-10 EP EP15777523.0A patent/EP3129362A4/en not_active Withdrawn
- 2015-04-10 WO PCT/US2015/025235 patent/WO2015157594A1/en active Application Filing
- 2015-04-10 MA MA039862A patent/MA39862A/fr unknown
- 2015-04-10 EA EA201691963A patent/EA032203B1/ru not_active IP Right Cessation
- 2015-04-10 CN CN201580031041.XA patent/CN106458942A/zh active Pending
- 2015-04-10 AR ARP150101089A patent/AR100006A1/es unknown
- 2015-04-10 SG SG11201608203RA patent/SG11201608203RA/en unknown
- 2015-04-10 UY UY0001036075A patent/UY36075A/es not_active Application Discontinuation
- 2015-04-10 MX MX2016013373A patent/MX2016013373A/es unknown
- 2015-04-10 NZ NZ725131A patent/NZ725131A/en not_active IP Right Cessation
- 2015-04-10 TW TW104111700A patent/TW201625662A/zh unknown
- 2015-04-10 AU AU2015243379A patent/AU2015243379B2/en not_active Ceased
- 2015-04-10 CA CA2945318A patent/CA2945318A1/en not_active Abandoned
-
2016
- 2016-08-08 US US15/230,918 patent/US10159745B2/en not_active Expired - Fee Related
- 2016-09-14 IL IL247822A patent/IL247822A0/en unknown
- 2016-10-06 CL CL2016002548A patent/CL2016002548A1/es unknown
- 2016-10-07 PH PH12016501995A patent/PH12016501995A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017510661A (ja) | 2017-04-13 |
US10159745B2 (en) | 2018-12-25 |
PH12016501995A1 (en) | 2017-01-09 |
CA2945318A1 (en) | 2015-10-15 |
EA201691963A1 (ru) | 2017-06-30 |
EP3129362A4 (en) | 2017-08-23 |
AR100006A1 (es) | 2016-08-31 |
MX2016013373A (es) | 2017-05-02 |
TW201625662A (zh) | 2016-07-16 |
WO2015157594A1 (en) | 2015-10-15 |
UY36075A (es) | 2015-10-30 |
AU2015243379A1 (en) | 2016-11-03 |
SG11201608203RA (en) | 2016-10-28 |
IL247822A0 (en) | 2016-11-30 |
US20160339114A1 (en) | 2016-11-24 |
NZ725131A (en) | 2018-03-23 |
KR20160142392A (ko) | 2016-12-12 |
MA39862A (fr) | 2017-02-15 |
AU2015243379B2 (en) | 2018-02-01 |
EA032203B1 (ru) | 2019-04-30 |
EP3129362A1 (en) | 2017-02-15 |
US9427479B2 (en) | 2016-08-30 |
US20150291657A1 (en) | 2015-10-15 |
CN106458942A (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016002548A1 (es) | Derivados de tubulisina | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2016002394A1 (es) | Derivados de quinolina como inhibidores de smo | |
CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
CL2016003398A1 (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo. | |
CO2017011484A2 (es) | Inhibidores de bromodominio | |
CL2016002735A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
CL2016000922A1 (es) | Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4 | |
CL2015002394A1 (es) | Inhibidores de histona desmetilasas | |
CL2016001737A1 (es) | Derivados heterocíclicos bicíclicos como inhibidores de bromodominio | |
MA54253A (fr) | Procédé de préparation de dérivés de 2-chloro-4-hétéroaryl-pyridimidines | |
CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
GT201400297A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
DK3319993T3 (da) | AXL-SPECIFIKKE antistof-lægemiddelkonjugater til kræftbehandling | |
ES2721001T3 (es) | Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa | |
CL2017002170A1 (es) | Desacetoxitubulisina h y análogos de esta. | |
MX2021001231A (es) | Compuestos heterociclicos y sus usos. | |
DK3539961T3 (da) | Polycykliske amidderivativer som cdk9-inhibitorer | |
CO2017000065A2 (es) | Indoles funcionalizados y sustituidos como agentes anti-cáncer | |
CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
MX2016009663A (es) | Derivados de icariina. | |
UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 |